Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP

Blood Adv. 2021 Aug 10;5(15):2965-2968. doi: 10.1182/bloodadvances.2021004766.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Central Nervous System
  • Humans
  • Incidence
  • Lenalidomide
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Lymphoma, Large B-Cell, Diffuse* / epidemiology
  • Neoplasm Recurrence, Local* / drug therapy

Substances

  • Lenalidomide